Panacea Biotec Ltd
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]
- Market Cap ₹ 882 Cr.
- Current Price ₹ 144
- High / Low ₹ 202 / 112
- Stock P/E 249
- Book Value ₹ 53.7
- Dividend Yield 0.00 %
- ROCE 4.08 %
- ROE 1.08 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 2.50 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -15.8% over last 3 years.
- Contingent liabilities of Rs.640 Cr.
- Earnings include an other income of Rs.24.9 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 596 | 498 | 679 | 647 | 530 | 184 | 96 | 158 | 344 | 236 | 257 | 360 | |
| 653 | 586 | 612 | 534 | 460 | 192 | 243 | 248 | 343 | 308 | 320 | 345 | |
| Operating Profit | -57 | -88 | 68 | 113 | 70 | -8 | -147 | -90 | 0 | -73 | -63 | 14 |
| OPM % | -10% | -18% | 10% | 17% | 13% | -4% | -152% | -57% | 0% | -31% | -24% | 4% |
| -5 | 304 | 28 | 75 | 16 | 84 | 322 | -14 | 21 | 13 | 34 | 25 | |
| Interest | 106 | 148 | 93 | 115 | 104 | 103 | 105 | 5 | 8 | 7 | 10 | 14 |
| Depreciation | 84 | 69 | 66 | 71 | 66 | 34 | 33 | 27 | 27 | 26 | 24 | 21 |
| Profit before tax | -251 | -0 | -63 | 1 | -84 | -61 | 37 | -136 | -13 | -94 | -63 | 4 |
| Tax % | 8% | -0% | -3% | 38% | 14% | -17% | 29% | -13% | -12% | -0% | -40% | 16% |
| -230 | -0 | -65 | 1 | -73 | -72 | 27 | -153 | -14 | -94 | -88 | 4 | |
| EPS in Rs | -37.54 | -0.07 | -10.64 | 0.14 | -11.85 | -11.73 | 4.33 | -24.97 | -2.36 | -15.27 | -14.28 | 0.58 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | 30% |
| 3 Years: | 2% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 15% |
| 3 Years: | 30% |
| TTM: | 104% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -1% |
| 3 Years: | -31% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | -17% |
| 5 Years: | -13% |
| 3 Years: | -16% |
| Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 555 | 556 | 517 | 518 | 450 | 382 | 412 | 855 | 502 | 409 | 320 | 323 |
| Preference Capital | -0 | -0 | 16 | 16 | -0 | 9 | -0 | -0 | -0 | -0 | -0 | |
| 922 | 990 | 1,015 | 1,019 | 1,023 | 960 | 689 | 67 | 65 | 84 | 102 | 125 | |
| 197 | 334 | 341 | 265 | 303 | 325 | 335 | 211 | 217 | 263 | 296 | 300 | |
| Total Liabilities | 1,680 | 1,886 | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 |
| 959 | 1,086 | 1,060 | 988 | 942 | 891 | 496 | 499 | 464 | 454 | 435 | 449 | |
| CWIP | 28 | 26 | 17 | 19 | 28 | 37 | 3 | 4 | 13 | 1 | 28 | 71 |
| Investments | 272 | 394 | 395 | 395 | 345 | 345 | 3 | 3 | 0 | 0 | 0 | 0 |
| 422 | 380 | 408 | 406 | 467 | 401 | 940 | 633 | 313 | 307 | 260 | 234 | |
| Total Assets | 1,680 | 1,886 | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -39 | 53 | 45 | 98 | 104 | 172 | 107 | -83 | 38 | -53 | -11 | 37 | |
| -14 | -18 | -29 | 23 | -18 | -3 | -10 | -17 | -37 | 40 | 2 | -51 | |
| 55 | -38 | -11 | -129 | -91 | -164 | -98 | 109 | -7 | 10 | 9 | 13 | |
| Net Cash Flow | 1 | -3 | 5 | -8 | -5 | 6 | -2 | 10 | -6 | -3 | 1 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 42 | 66 | 54 | 80 | 121 | 283 | 96 | 41 | 37 | 36 | 17 | 11 |
| Inventory Days | 316 | 310 | 178 | 233 | 304 | 618 | 203 | 619 | 180 | 421 | 260 | 278 |
| Days Payable | 216 | 397 | 236 | 295 | 490 | 1,002 | 373 | 847 | 257 | 472 | 289 | 316 |
| Cash Conversion Cycle | 141 | -20 | -4 | 17 | -65 | -102 | -74 | -188 | -39 | -15 | -12 | -27 |
| Working Capital Days | 65 | -143 | -57 | 43 | 18 | -297 | 215 | 900 | 8 | -63 | -138 | -97 |
| ROCE % | -9% | -9% | 2% | 4% | 4% | 3% | -14% | -8% | -1% | -16% | -13% |
Documents
Announcements
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
1d - NSE and BSE Ltd. have, vide their notice / email dated July 01, 2024, imposed a fine of Rs.11,800 each (inclusive of GST) for non-compliance …
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
2d - The Company has received today, a copy of Request for Arbitration filed by Human Vaccine Limited Liability Company, Russia with London court of International Arbitration …
- Closure of Trading Window 27 Jun
- Intimation Regarding Change In Senior Management Personnel Of The Company'S Material Subsidiary Viz. Panacea Biotec Pharma Limited 26 Jun
-
Intimation Of Incorporation Of Step-Down Subsidiary Company
22 Jun - The Company''s material subsidiary, Panacea Biotec Pharma Ltd. has incorporated its wholly owned subsidiary company namely, Panacea Biotec Inc. in the state of Delaware, USA …
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix